| Pair Name | Acteoside, Thymic stromal lymphopoietin | ||
| Phytochemical Name | Acteoside (PubChem CID: 5281800 ) | ||
| Anticancer drug Name | Thymic stromal lymphopoietin (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Acteoside, Thymic stromal lymphopoietin | |||
| Disease Info | [ICD-11: 2B33.4] | Leukemia | Investigative | |
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Down-regulation | Expression | IL1B | hsa3553 | |
| Down-regulation | Expression | IL6 | hsa3569 | |
| Down-regulation | Expression | MDM2 | hsa4193 | |
| Down-regulation | Expression | TNF | hsa7124 | |
| In Vitro Model | HMC-1 | Mast cell leukemia | Homo sapiens (Human) | CVCL_0003 |
| Result | These results indicate that acteoside is a specific regulator of MDM2 activation in TSLP-stimulated mast cells, which indicates its potential use for the treatment of mast cell-mediated inflammatory diseases. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Acteoside attenuates TSLP-induced mast cell proliferation via down-regulating MDM2. Int Immunopharmacol. 2015 May;26(1):23-9. doi: 10.1016/j.intimp.2015.03.003. | Click |
